EA201301232A1 - Лекарственная форма для целевого высвобождения активных веществ - Google Patents

Лекарственная форма для целевого высвобождения активных веществ

Info

Publication number
EA201301232A1
EA201301232A1 EA201301232A EA201301232A EA201301232A1 EA 201301232 A1 EA201301232 A1 EA 201301232A1 EA 201301232 A EA201301232 A EA 201301232A EA 201301232 A EA201301232 A EA 201301232A EA 201301232 A1 EA201301232 A1 EA 201301232A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dosage form
active substances
targeting
active substance
release
Prior art date
Application number
EA201301232A
Other languages
English (en)
Other versions
EA025128B1 (ru
Inventor
Гернот Франкас
Карл-Хайнц Прцикленк
Original Assignee
Хенниг Арцнаймиттель Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201110075354 external-priority patent/DE102011075354A1/de
Application filed by Хенниг Арцнаймиттель Гмбх Унд Ко. Кг filed Critical Хенниг Арцнаймиттель Гмбх Унд Ко. Кг
Publication of EA201301232A1 publication Critical patent/EA201301232A1/ru
Publication of EA025128B1 publication Critical patent/EA025128B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Abstract

Настоящее изобретение относится к лекарственной форме, способу её получения и её применению. Лекарственная форма содержит разные содержащие активное вещество единицы, предназначенные для высвобождения активного вещества так, чтобы можно было моделировать неоднократный дневной приём традиционной лекарственной формы. Лекарственная форма может высвобождать несколько активных веществ.
EA201301232A 2011-05-05 2012-05-02 Лекарственная форма для целевого высвобождения активных веществ EA025128B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011075356 2011-05-05
DE201110075354 DE102011075354A1 (de) 2011-05-05 2011-05-05 Arzneiform zur gezielten Freigabe von Wirkstoffen
PCT/EP2012/057996 WO2012150246A1 (de) 2011-05-05 2012-05-02 Arzneiform zur gezielten freigabe von wirkstoffen

Publications (2)

Publication Number Publication Date
EA201301232A1 true EA201301232A1 (ru) 2014-03-31
EA025128B1 EA025128B1 (ru) 2016-11-30

Family

ID=46046170

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301232A EA025128B1 (ru) 2011-05-05 2012-05-02 Лекарственная форма для целевого высвобождения активных веществ

Country Status (8)

Country Link
EP (1) EP2704698B1 (ru)
EA (1) EA025128B1 (ru)
ES (1) ES2755075T3 (ru)
HU (1) HUE047420T2 (ru)
LT (1) LT2704698T (ru)
PL (1) PL2704698T3 (ru)
PT (1) PT2704698T (ru)
WO (1) WO2012150246A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013369379B2 (en) * 2012-12-27 2018-03-15 Hennig Arzneimittel Gmbh & Co. Kg Monolithic dosage form for the modified release of an active ingredient combination
LT2959887T (lt) 2014-06-26 2019-03-12 Hennig Arzneimittel Gmbh&Co. Kg Vaistai galvos svaigimo, atsiradusio dėl įvairių priežasčių, gydymui
WO2018115888A1 (en) * 2016-12-21 2018-06-28 N4 Pharma Uk Limited Novel formulations of aprepitant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262173A (en) 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US6599529B1 (en) 1997-09-11 2003-07-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
GB2414668B (en) 2004-06-03 2009-07-29 Dexcel Ltd Tetracycline modified release delivery system
WO2006078811A2 (en) * 2005-01-21 2006-07-27 Pharmanova Inc. Pharmaceutical formulations and methods of use
DE102005014142B4 (de) 2005-03-23 2006-11-09 Hennig Arzneimittel Gmbh & Co. Kg Pelletförmige Retardzubereitung gegen Schwindel
WO2006099886A1 (de) 2005-03-24 2006-09-28 Eska Implants Gmbh & Co. Set zur erstellung eines grosszehengrundgelenkes
US20080193537A1 (en) 2005-05-13 2008-08-14 Alpharma, Inc. Morphine Sulfate Formulations
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
AU2006337643A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Dipyridamole extended-release formulations and process for preparing same

Also Published As

Publication number Publication date
EP2704698B1 (de) 2019-10-02
EA025128B1 (ru) 2016-11-30
HUE047420T2 (hu) 2020-04-28
LT2704698T (lt) 2019-11-25
EP2704698A1 (de) 2014-03-12
WO2012150246A1 (de) 2012-11-08
PL2704698T3 (pl) 2020-01-31
PT2704698T (pt) 2019-11-19
ES2755075T3 (es) 2020-04-21

Similar Documents

Publication Publication Date Title
EA201591166A1 (ru) Ингибиторы аутотаксина
IL265707A (en) Pharmaceutical preparations containing human antibodies to pcsk9
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201600506A1 (ru) КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA202190619A1 (ru) Противовирусные соединения
EA201400579A1 (ru) Антитела к il-36r
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201300388A1 (ru) Соединения замещенного бензамида
EA201401204A1 (ru) Антитела к il-23p19
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201490037A1 (ru) Антагонисты trpv4
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201591618A1 (ru) Замещенные имидазопиридазины
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
EA201390467A1 (ru) Композиции антител и способы применения